CoChat

Cumulative antibiotic use and efficacy of immune checkpoint inhibitors in patients with advanced cancer.

Tinsley, Nadina, Zhou, Cong, Villa, Shaun, Tan, Grace, Lorigan, Paul, Blackhall, Fiona Helen, Elliott, Tony, Krebs, Matthew, Carter, Louise, Thistlethwaite, Fiona, Hughes, Andrew, Cook, Natalie · 2018 · Journal of Clinical Oncology
Cited by 26

The DOI matches its Crossref record.

Abstract

3010 Background: Efficacy of immune checkpoint inhibitors (CKIs) for treatment of cancer may be affected by the use of antibiotics (ABX). The gut microbiome is involved in immunotherapy responses therefore ABX known to alter the gut microbiome may affect tumour inflammation and microenvironment, leading to decreased CKI efficacy. Methods: Retrospective data analysis was undertaken on metastatic cancer patients (pts) treated with CKIs between January 2015 and March 2017 at the Christie NHS Foundation Trust. Melanoma, renal and non-small cell lung cancer (NSCLC) pts were included. Demographics, prior systemic treatment, extent of disease, CKI agent and use of ABX (route, duration, multiple concurrent/successive courses) were collected. Progression free survival (PFS) and overall survival (OS) were compared between ABX groups (ABX + defined as pts treated with ABX within 2 weeks of CKI initiation or 6 weeks after, ABX – as pts with no ABX during specified period). Statistical analyses were performed with univariate and multivariate models. Results: Of 303 included pts (201 (66%) melanoma, 56 (18%) NSCLC and 46 (15%) renal) 94 (31%) received ABX (commonest beta-lactam ABX and macrolides). In multivariate analysis, ABX + pts had shorter PFS and OS when compared to ABX – pts: PFS 97 days (95% CI 84-122) vs 178 days (95% CI 155-304) p = 0.049; OS 317 days (95% CI 221-584) vs 651 days (95% CI 477-998) p = 0.001. Cumulative ABX ( > 10 days, multiple concurrent/successive courses) demonstrated particularly shortened PFS 87 days (95% CI 83-122) p = 0.0093 and OS 193 days (95% CI 96-355) p = 0.00021. Pts treated with ABX prior to CKI initiation had shorter PFS and OS than those treated after CKI initiation (HR 1.37 and HR 1.72) p = 0.29 and 0.08 respectively. Conclusions: To our knowledge, this is the largest multivariate analysis showing ABX use is an independent predictor of shorter PFS and OS in cancer pts treated with CKI. It is the first analysis to demonstrate cumulative ABX use is associated with even poorer outcomes across multiple tumour types independent of clinical factors. The data suggests a trend towards reduced PFS in pts who received ABX prior to CKI initiation, warranting further validation in a larger cohort.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2018.36.15_suppl.3010

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 26

Metadata

Authors
Tinsley, N., Zhou, C., Villa, S., Tan, G., Lorigan, P., Blackhall, F. H., Elliott, T., Krebs, M., Carter, L., Thistlethwaite, F., Hughes, A., & Cook, N.
Venue
Journal of Clinical Oncology
Published
2018-05-20
Volume
36
Issue
15_suppl
Pages
3010-3010
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2885920111
Cited by
26
References
0
Type
conference abstract
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cumulative antibiotic use and efficacy of immune checkpoint inhibitors in patients with advanced cancer. https://app.cochat.ai/papers/10.1200/jco.2018.36.15_suppl.3010
The paper
Tinsley, N., Zhou, C., Villa, S., Tan, G., Lorigan, P., Blackhall, F. H., Elliott, T., Krebs, M., Carter, L., Thistlethwaite, F., Hughes, A., & Cook, N. (2018). Cumulative antibiotic use and efficacy of immune checkpoint inhibitors in patients with advanced cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2018.36.15_suppl.3010

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.